title: CCR 20th Anniversary Commentary: Simpson's Paradox and Neoadjuvant Trials.
abstract: The research article by Carey and colleagues, published in the April 15, 2007, issue of Clinical Cancer Research, described the relationship between response to neoadjuvant chemotherapy and outcome by tumor subtype. Today neoadjuvant clinical trials are often designed to provide correlative data to help identify predictive biomarkers or to focus on poor-risk patients identified by residual disease after neoadjuvant treatment.
authors.affiliation: The University of North Carolina, Chapel Hill, North Carolina. lisa_carey@med.unc.edu.
authors.forename: Lisa A
authors.initials: LA
authors.lastname: Carey
mesh_terms: D014408:Biomarkers, Tumor; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant / Q000379:methods*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008495:Medical Oncology / Q000379:methods / Q000639:trends; D020360:Neoadjuvant Therapy / Q000379:methods*; D018365:Neoplasm, Residual / Q000188:drug therapy*; D012107:Research Design; D012307:Risk Factors; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy
chemical_list: D014408:Biomarkers, Tumor